

# Impact of Physiological Fluctuations of Sex Hormones During the Menstrual Cycle on Glucose Metabolism and the Gut Microbiota



## Authors

Alina Schieren<sup>1‡</sup>, Sandra Koch<sup>1‡</sup>, Tal Pecht<sup>2, 3</sup>, Marie-Christine Simon<sup>1</sup>

## Affiliations

- 1 University of Bonn, Institute of Nutrition and Food Sciences, Nutrition and Microbiota, Bonn, Germany
- 2 University of Bonn, Life & Medical Sciences (LIMES) Institute, Department for Genomics and Immunoregulation, Bonn, Germany
- 3 German Center for Neurodegenerative Diseases (DZNE), Systems Medicine, Bonn, Germany

## Keywords

menstrual cycle, diabetes, autoimmunity, insulin resistance, intestinal microbiome, female health, glucose homeostasis

received 15.08.2023

revised 10.01.2024

accepted 18.01.2024

accepted manuscript online 21.02.2024

published online 10.04.2024

## Bibliography

Exp Clin Endocrinol Diabetes 2024; 132: 267–278

DOI 10.1055/a-2273-5602

ISSN 0947-7349

© 2024. The Author(s).

This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (<https://creativecommons.org/licenses/by-nc-nd/4.0/>)

Georg Thieme Verlag KG, Rüdigerstraße 14,  
70469 Stuttgart, Germany

## Correspondence

Marie-Christine Simon

University of Bonn

53115 Bonn

Germany

Tel.: +49 228 73 3814

marie-christine.simon@uni-bonn.de

## ABSTRACT

Diabetes mellitus is one of the most prevalent chronic diseases. Previous studies have shown differences in glucose metabolism between males and females. Moreover, difficulties in medication adherence have been reported in females with type 2 diabetes. These observations are believed to be caused by fluctuations in sex hormone concentrations during the menstrual cycle. Furthermore, gut microbiota is linked to female host metabolism and sex hormone production. Understanding the interactions between fluctuating hormone concentrations during the menstrual cycle, gut microbiota, and glucose metabolism in humans is significant because of the increasing prevalence of diabetes and the consequent need to expand preventive efforts. A literature search was performed to determine and summarize the existing evidence, deduce future research needs to maintain female health, and investigate the relationship between the physiological menstrual cycle and glucose metabolism. Studies from 1967 to 2020 have already examined the relationship between variations during the menstrual cycle and glucose metabolism in healthy female subjects using an oral-glucose tolerance test or intravenous glucose tolerance test. However, the overall number of studies is rather small and the results are contradictory, as some studies detected differences in glucose concentrations depending on the different cycle phases, whereas others did not. Some studies reported lower glucose levels in the follicular phase than in the luteal phase, whereas another study detected the opposite. Data on gut microbiota in relation to the menstrual cycle are limited. Conflicting results exist when examining the effect of hormonal contraceptives on the gut microbiota and changes in the course of the menstrual cycle. The results indicate that the menstrual cycle, especially fluctuating sex hormones, might impact the gut microbiota composition.

The menstrual cycle may affect the gut microbiota composition and glucose metabolism. These results indicate that glucose tolerance may be the greatest in the follicular phase; however, further well-conducted studies are needed to support this assumption.

## Introduction

Cardiovascular diseases, cancer, chronic respiratory diseases, and diabetes mellitus are the most common non-communicable chronic

ic diseases worldwide, causing 41 million deaths annually [1]. In 2021, diabetes affected approximately 10.5% (536.6 million) of the global population aged 20–79 years. Its prevalence is expected to increase to 12.2% by 2045, indicating its high relevance in the prevention and treatment of diabetes [2].

‡ Equal contribution: Alina Schieren, Sandra Koch

Early studies have shown that men and women respond differently to oral-glucose tolerance test (OGTT) [3, 4], which is used to assess glucose tolerance. Moreover, OGTT is used as a reference method for diagnosing type 2 diabetes in unclear cases, according to the current German guidelines [5]. Similar results were observed for insulin sensitivity; however, these findings are contradictory [6]. On the one hand, reduced insulin sensitivity in young normal-weight women as compared to men [7]; subsequent differences in postprandial glucose metabolism have been reported [8]. In contrast, in another study, normal-weight women (<40 years) had higher insulin sensitivity than men of the same age [9]; no differences in plasma insulin concentrations between normal-weight men and women were found in other studies [10, 11].

Additional studies detected an interaction between diabetes and the female menstrual cycle, including a higher prevalence of oligomenorrhea, increased cycle duration, and glycemic variations along the cycle phases [12, 13]. Furthermore, difficulties in medication management in women with diabetes during different menstrual cycle phases have been reported, [14, 15] with a higher risk of hypoglycemia in the follicular phase (FP) and hyperglycemia in the luteal phase (LP) [16]. In addition, Ezenwaka et al. detected higher insulin resistance in the LP than in the FP [17]. These observations may be due to the fluctuating sex hormone concentrations during the menstrual cycle, which may be associated with glucose tolerance [18].

Similar to glucose tolerance, the gut microbiota shows sex-dependent differences in animal and human studies [19] and has been associated with the metabolism of female sex hormones [20, 21]. In addition, alterations in the microbiota can play a role in the pathogenesis of type 2 diabetes by dysregulating host-microbiota interactions via various pathways, such as intestinal hormones or inflammatory reactions. A low-grade inflammatory state, which has been associated with insulin resistance and type 2 diabetes [22], can be affected by certain gut microbes or their metabolites, which can increase the levels pro- or anti-inflammatory cytokines, inhibit inflammatory cytokines and chemokines, or modulate the intestinal barrier function as well as the secretion of gut hormones. For example, the levels of anti-inflammatory cytokines IL-10 and IL-22, can be increased by certain microbes and have been shown to protect against insulin resistance in muscles and improve insulin sensitivity. Moreover, short-chain fatty acids, butyrate, and propionate produced by bacteria can regulate gut permeability [23, 24] and enhance gut hormone release of glucagon-like peptide 1 (GLP-1), glucagon-like peptide 2 (GLP-2), and peptide YY (PYY), thereby affecting insulin secretion and glucose homeostasis [25–27].

Therefore, this review aims to reveal the nature of the mutual relationship of glucose metabolism and gut microbiota with the menstrual cycle, particularly for better prevention and management of diabetes in women.

## Relationship between the menstrual cycle and glucose metabolism

The menstrual cycle is characterized by cyclic changes in reproductive hormones and structural changes in the ovaries and endometrium. Under normal physiologic conditions, oocyte maturation occurs in a cyclical pattern over approximately 28 days and results


from the interaction of various organs and hormones: ovaries, uterus, pituitary gland, luteinizing hormone (LH), follicle-stimulating hormone (FSH), estrogen, and progesterone. A regular menstrual cycle length is between 25 and 35 days [28]; recent studies have shed light on the high variability within the population that is dependent on ethnicity, age, and body mass index (BMI) and reported that the average menstrual cycle extends over 29.3 days [29]. The same study reported that menstrual bleeding, which marks the beginning of the menstrual cycle [28], has an average duration of 4 days [29]. The menstrual cycle can be divided according to the changes in the ovaries or uterus, referred to as the ovarian or uterine cycle, respectively. The FP and LP phases of the ovarian cycle occur alongside the menstrual (MP), proliferative (PP), and secretory (SP) phases of the uterine cycle. The individual phases, corresponding hormone fluctuations, and hypothetical curves of glucose, insulin, and HOMA are shown in ► **Fig. 1** and are discussed in the following paragraphs. A healthy woman goes through the menstrual cycle monthly, from the beginning of her first menstrual bleeding (menarche) to menopause, defined as 12 months without menses [28].

Epidemiological studies showing a higher prevalence of diabetes in men than in women have sparked interest in investigating the role of sex hormones in diabetes susceptibility and the underlying metabolic changes [30]. This was further supported by data showing an increased risk of type 2 diabetes in women with early menopause or premature ovarian insufficiency [31] and a reduced incidence in postmenopausal women receiving hormonal therapy [32, 33], thereby indicating a protective effect of estrogens. Variations in hormones during the menstrual cycle influence glucose tolerance in women differently, as abnormal levels of female sex hormones may play a role in the pathogenesis of impaired fasting glucose and glucose tolerance [18].

## Impact of the menstrual cycle on glucose tolerance

To date, studies examining the influence of menstrual cycle phases on glucose metabolism via OGTTs [34–42] in humans are scarce and have provided contradictory results. Five of nine observational studies showed no significant differences in glucose levels during OGTT between different cycle phases [36, 38–40, 42], whereas four studies showed significant differences [34, 36, 37, 41]. In three of these four studies, glucose levels were significantly lower in the FP than in the LP [34, 37, 41]; Walsh and O'Sullivan reported the opposite result [36]. All studies examined healthy women with regular menstrual cycles. The women included were between 19 and 39 years of age and had a normal BMI or body weight. None of the studies included male controls. Most studies examined the same participants at two to four different time points of their menstrual cycle, whereas two studies [38, 40], and Peppler et al. in a subgroup [37] assessed participants at only one time-point. Details on the age and BMI of the participants, methodology, and results of the studies are presented in ► **Table 1**.

The results of Jarrett and Graver using an OGTT indicated variations in glucose tolerance between different menstrual cycle phases. The cycle phases in which the OGTTs were performed were not precisely defined; therefore, the results should be interpreted with caution. However, the examination times could be roughly assigned to the FP and LP. Accordingly, blood glucose levels were low during



► **Fig. 1** Schematic curves of ovarian and pituitary hormone concentrations as well as hypothetical curves for glucose and insulin levels and HOMA along the course of the menstrual cycle phases (figure adapted from ► **fig. 2** by Welt et al. [103]). Created with BioRender.com [rerif]

the FP and elevated during ovulation [34]. Pepler et al. and Brennan et al. reported congruent results [37, 41], indicating that glucose tolerance was greatest at the beginning of the cycle and decreased after ovulation (► **Fig. 2**). Walsh and O’Sullivan showed minor but statistically significant differences in glucose values between different menstrual cycle phases when adjusted for the time point in the cycle when the tests were performed [36]. However, contrary to the findings of the three other studies by Jarrett and Graver, Pepler et al., and Brennan et al., they found higher glucose levels at the beginning of the cycle (FP) as compared to the end of the cycle (LP). Thus, studies by Jarrett and Graver, Walsh and O’Sullivan, Pepler et al., and Brennan et al. indicated that the time point of the menstrual cycle at which an OGTT is performed in women is relevant and should be considered when investigating glucose metabolism.


Contrary to these results, Cudworth and Veevers, Bonora et al., Toth et al., and Busby et al. found no differences in glucose levels during an OGTT between the examined menstrual cycle time points. Williams et al., who compared early and late FP, did not detect any differences in glucose tolerance. Interestingly, in the studies showing differences in glucose levels, lower amounts of glucose (50 g) were used for the OGTT [34, 36, 37, 41] as compared to the studies that detected no differences (67–100 g glucose) [35, 38–

40, 42]. This might be due to the strong amplification of the physiological processes of glucose metabolism during an OGTT with a higher glucose load, which may potentially mask more subtle phase-specific effects on glucose metabolism. It would be interesting to address this hypothesis in future studies by comparing the effects of different glucose-loading levels.

### Impact of sex hormones on insulin secretion

The mechanisms underlying the influence of sex hormones on insulin secretion are not yet fully understood, as they appear to be tissue-specific and exert their effects via various metabolic, genomic, endocrine, and immunological pathways [43]. Possible mechanisms include direct effects on the pancreas by estrogen- or progesterone-binding receptors [44], hormonal influences on glucose uptake via glucose transporters, hormone-sensitive lipase expression in adipose tissue, and general changes in gene expression and cell function (e. g., in the liver) [45].

Data from human studies on insulin secretion in relation to the menstrual cycle phases are contradictory. Insulin levels were not measured in all studies that performed an OGTT to assess glucose tolerance; however, the results were consistent with those observed for glucose levels. While Cudworth and Veevers, Bonora et al., Toth et al., and Williams et al. found no significant differences



**Fig. 2** Blood glucose (a) and insulin (b) concentrations and AUC values of glucose (c) and insulin (d) after an OGTT during FP and LP phases of the menstrual cycle (data are mean values based on Brennan et al., 2009). \* $p < 0.05$ . AUC, area under the curve; OGTT, oral glucose tolerance test; FP, follicular phase; LP, luteal phase.

in insulin secretion [35, 38, 39, 42], Walsh and O'Sullivan, and Brennan et al. detected differences that were in agreement with the described changes in glucose levels [36, 41]. Spellacy et al. performed two intravenous glucose tolerance tests (IVGTTs; 25 g of glucose infused as a 50% glucose solution over a period of 2 minutes) in 19 women, once in the PP and once in the SP. Blood insulin (and glucose) levels measured at different time points over the course of two hours did not differ significantly between the two menstrual cycle phases [46].

### Impact of sex hormones on insulin sensitivity

The effects of progesterone and the main estrogen, estradiol (E2), on insulin sensitivity have been investigated in female rats. The results showed that progesterone contributes to a decrease in insulin sensitivity, whereas E2 maintained insulin sensitivity. This indicates that female sex steroid hormones are important for regulating glucose homeostasis, insulin sensitivity, and insulin response in rats [47]. The protective effect of estrogen on insulin sensitivity, for example, via the estrogen receptor  $\alpha$  (ER $\alpha$ ), has also been demonstrated in mouse models [30]. As E2 levels rise and drop before and after ovulation, then rise to a lower level in the LP, while progesterone levels are increased in the LP, the associations observed in rats would align with the results from human studies showing decreased glucose tolerance in the LP. However, current results from human studies on the effects of fluctuating sex hormones on

insulin sensitivity in the course of the menstrual cycle are inconsistent [6–11, 48–50]. A decrease in insulin sensitivity has been observed in some studies in the LP [49, 51–53]. Hummel et al. showed that brain insulin action may also be important in this context; nasal application of insulin improved peripheral insulin sensitivity in women only in the FP, whereas this effect was absent in the LP. Moreover, they observed a significant interaction between a high estradiol: progesterone ratio (present in the FP) and this effect [54]. Concurrently, other studies reported no relationship between menstrual cycle phases and insulin sensitivity [39, 48, 55] or only when adjusting for confounding factors such as BMI, physical activity, or cardiorespiratory fitness [50]. Likewise, Bingley et al. detected no differences in insulin sensitivity between FP and LP when performing an IVGTT (0.3 g glucose/kg body weight infused as a 50% glucose solution over a period of one minute) with a bolus insulin infusion (0.03 U/kg body weight) 20 minutes after glucose infusion [55].

### Impact of age and body mass index on the menstrual cycle and glucose metabolism

Age and BMI are known to affect glucose metabolism [56, 57]. Accordingly, an increase in blood glucose levels has been observed with increasing age [40]. In addition, markers of insulin resistance are associated with older age and abnormal BMI [57]. The menstrual cycle is also influenced by age [58] and BMI [59]. Between the

► **Table 1** Study characteristics and significant results of the included observational studies investigating glucose metabolism in relation to the menstrual cycle.

Authors Country	Number of patients	Age (years)	BMI (kg/m <sup>2</sup> )	Sampling method	Sampling time points	Determination of cycle phases	Significant results
(Jarrett und Graver 1968) [34] n.s.	10	19–39	N/A	3–4 × 2-h OGTT (50 g Glc (Lucozade)) Capillary blood samples (earlobe) Blood glucose	3–4 visits at weekly interval, 3 of 10 ♀: measurements repeated over several cycles	Days calculated from the first day of bleeding; 2 ♀ ovulation determined by oral BBT	AUC glc values lowest at the beginning of MC, higher before ovulation, and maximum after ovulation
(Cudworth und Veevers 1975) [35] UK	20	Ø 19	BW: Ø 56.8	3 × 2-h OGTT (100 g Glc in 400 mL water, over 4 min) Venous blood samples Blood glucose, serum insulin	PP (day 9), SP (day 18), before MP (day 27) 7 of 20 ♀: repeated examinations in one more cycle	Days calculated from the first day of bleeding; ovulation not determined	No significant differences
(Walsh and O'Sullivan, 1975) [36] Ireland	33	Ø 23	N/A	4 × 2-h OGTT (50 g Glc in 200–500 mL flavored water, over 5 min) <sup>a</sup> Venous blood samples Plasma glucose, serum insulin	Four visits at weekly intervals	Days calculated from the first day of bleeding; ovulation not determined	Glc and insulin values <sup>b</sup> highest at the beginning of MC; $p < 0.05$ between all MC quarters for 0 (glc) and 30 min (glc and insulin)
(Pepler et al. 1978) [37] Germany	213 (109 without HC)	20–54	N/A	1 or 2 × 2-h OGTT (50 g Glc in 200 mL water) Capillary blood samples (earlobe) Blood glucose	MP, FP, LP	Classification by questionnaires; ovulation not determined	Glc values lowest at the beginning of MC; continued phase-specific glc behavior after stratification for HC intake
(Bonora et al. 1987) [38] Italy	FP: 55 LP: 55	Ø 36–37	Ø 23	1 × 2-h OGTT (75 g Glc)	FP (day 5–10), LP (day 20–25)	No information	No significant differences
(Toth et al., 1987) [39] Canada	6	Ø 25	Ø 22.5	Blood samples Plasma glucose and insulin 3 × 3-h OGTT (75 g Glc (Trutol))	MP (day 1–6), FP (day 9–14), LP (day 20–28)	Measurement of progesterone levels confirmed FP and LP	No significant differences
(Busby et al. 1992) [40] USA	Early FP: 29 Late FP: 21 LP: 40	Ø 35.5–36.5	Ø 22.2–22.7	Blood samples Plasma glucose and insulin 1 × 2-h OGTT (40 g Glc/m <sup>2</sup> body surface (Ø 67 g Glc)) Venous blood samples Plasma glucose	Early FP, late FP, LP	Measurement of E2 and progesterone levels confirmed early and late FP and LP; Ovulation not determined	No significant differences
(Brennan et al. 2009) [41] Norway	9	Ø 31	Ø 21	3 × 1.5-h OGTT (50 g Glc in 300 mL water, over 2 min) Venous blood samples Blood glucose, plasma insulin	FP in 2 MC (FP1 and FP2: day 6–12), LP (day 18–24)	E2 and progesterone measured	Glc and insulin values and AUC lowest at the beginning of MC; $p < 0.01$ for all (FP1/2 vs. LP) No differences between FP1 and FP2
(Williams et al. 2019) [42] Canada	17	Ø 21	Ø 22.2	2 × 0.5-h OGTT (75 g Glc in 300 mL water, over 3 min) Venous blood samples Blood glucose and insulin	Early FP (day 2–6), late FP (3 ± 2 days before ovulation)	Days calculated from the first day of bleeding; ovulation determined by ovulation kit	No significant differences

All studies included healthy women with a regular menstrual cycle. Only significant results shown ( $p < 0.05$ ); OGTTs were performed in sitting position, unless otherwise indicated; ♀, women; Ø, mean; <sup>a</sup> design according to "British Diabetic Association"; <sup>b</sup> values adjusted for the study time point; AUC, area under the curve; BBT, basal body temperature; BW, body weight; E2, estradiol; FP, follicular phase; Glc, glucose; HC, hormonal contraceptives; N/A, not available; n.s., not specified; LP, luteal phase; min, minutes; MP, menstrual phase; MC, menstrual cycle; OGTT, oral glucose tolerance test; PP, proliferation phase; SP, secretion phase; UK, United Kingdom; USA, United States of America.



ages of 40 and 55 years, changes in follicle recruitment occur [58], and menopause sets in [28]. Menstruation and LP may last longer in women with obesity (defined by a BMI > 30 kg/m<sup>2</sup>) and they are less likely to experience an increase in LH levels, possibly resulting from an absence of ovulation [59]. In addition, severe weight loss, such as in anorexia nervosa, can result in amenorrhea [60]. Energy intake and expenditure, which may be affected by the menstrual cycle, are important in regulating glucose metabolism and affect the BMI. Using an ad libitum buffet meal, Brennan et al. reported that study participants consumed a significantly lower amount of food (measured in grams and kilojoules) in the FP than in the LP [41]. These observations are consistent with those of previous studies on energy expenditure [61] and the basal metabolic rate [62] during the menstrual cycle. Webb et al. reported an increase in energy expenditure during the LP [61]. In agreement with this is the decrease in the basal metabolic rate during the menstrual phase (MP), the minimum basal metabolic rate one week before ovulation, and the increasing basal metabolic rate after ovulation [62]. MacGregor et al. found that the rhythmicity of insulin sensitivity during the menstrual cycle was modified by BMI [50].

Therefore, age, BMI (as an indicator of the nutritional status of the participants), and diet plus basal metabolic rate should be considered when evaluating the results of studies examining the menstrual cycle (► Fig. 3). However, in some OGTT studies, clear information on the age and BMI of the study participants was missing.

### Impact of health status and medication on the menstrual cycle and glucose metabolism

In addition to age and BMI, markers of insulin resistance and sensitivity are associated with factors that indicate health status, such as physical activity and cardiorespiratory fitness [50, 57]. Peppler et al. and Jarrett and Graver provided no information on the medication or health status of their participants, both of which can influence glucose metabolism [63]. Although discussing the effects of hormonal contraceptives on glucose metabolism is beyond the scope of this review, it is important to note that physiological fluctuations in female sex hormones are affected by hormonal contraceptive intake. Synthetic steroid analogs used in contraceptives induce metabolic effects, affecting liver metabolism and protein synthesis; however [64], the influence of hormonal contraceptives on glucose metabolism is sparse and shows contradictory results. Some studies have shown that oral steroid contraceptives may affect insulin sensitivity. Peppler et al. detected 10–20 mg/dl higher glucose levels in women who used hormonal contraceptives than in those who did not [37]. In addition, in another study, hormonal contraceptives were associated with an increased insulin reaction, depending on the type and dose of progestogen [65]. Perseghin et al. recorded a decrease in insulin sensitivity of 40% compared to women not using contraceptives [11]. On the other hand, in another examination, various hormonal contraceptives did not reveal any impairment of glucose metabolism [66].

### Impact of pregnancy on glucose tolerance

Although a detailed assessment of the effects of hormonal changes on glucose metabolism during pregnancy is beyond the scope of this review, it is important to note that pregnancy can affect glucose metabolism in women of normal weight by reducing insulin

sensitivity [67]. Furthermore, there are various risk factors for the development of gestational diabetes during pregnancy (e. g., maternal BMI > 27 kg/m<sup>2</sup> before pregnancy, advanced age, and family history of diabetes). Due to gestational diabetes, the risk of developing type 2 diabetes within 10 years of gestation is 8- to 10-times higher [68]. Owing to the lack of information on the subjects in most studies, it is unclear whether they belong to the risk group for type 2 diabetes.

### Methodological aspects and their interaction with data on glucose tolerance along the menstrual cycle

The methodological and technical characteristics of the studies, such as the OGTT procedure, blood sampling methods, time points of glucose measurement, and examined time points (phases of the menstrual cycle), have an impact on the results. Therefore, well-designed studies focusing on these aspects with proper documentation should be conducted.


### Impact of test procedure on glucose values

According to World Health Organization (WHO) guidelines, an amount of 75 g of glucose (or 82.5 g of glucose monohydrate) is recommended for the standard OGTT [69]. Unfortunately, the studies in which OGTTs were performed differed in the amounts of glucose and water, making a comparison of blood glucose values between different studies difficult.

Oral glucose administration affects gastric emptying. The release of GLP-1 induced by oral glucose administration was greater in the LP than in the FP. In this context, faster gastric emptying also occurs in the LP [41]. Moreover, glucose concentrations 15 and 30 minutes after glucose administration are directly related to the rate of gastric emptying [70]. Thus, gastric emptying affects the glucose levels after oral glucose loading and appears to be influenced by the cycle phase.

Other factors that may be related to gastric emptying and may affect glucose absorption are food restrictions and physical activity on the day prior to administering OGTT. According to the WHO guidelines, the performance of an OGTT should follow a three-day diet with at least 150 g of carbohydrate per day [69]. Therefore, in future studies, this should be the standard procedure before performing an OGTT by means of standardized meals or the provision of appropriate recipes. Accordingly, limiting physical activity the day before the OGTT is also relevant to avoid influencing the results [71]. Adherence to the WHO guidelines may help compare data and shed light on the expected slight differences in glucose metabolism depending on the menstrual cycle phases.

Neither of the two studies that performed the IVGTT showed any differences between the menstrual cycle phases [46, 55]. Since the IVGTT is a very accurate and sensitive method for measuring first-phase insulin secretion of the pancreas, as the gastrointestinal tract and thus the incretin effect is bypassed [72, 73], the strong effects induced by the intravenous glucose injection might have concealed the effects of the menstrual cycle on glucose homeostasis. This is in line with the results of the OGTTs with a higher glucose load and might indicate that test methods that induce higher blood glucose levels, and thus higher insulin secretion and glucose uptake, might overshadow the phase-specific effects on glucose metabolism, which are expected to be more subtle. In addition, the



► **Fig. 3** Various factors such as age, BMI, diet, physical activity as well as medication, health status, and pregnancy play a role in the mutual relationship of fluctuating sex hormones in the course of the menstrual cycle with glucose metabolism and the gut microbiota. BMI, body mass index; SCFAs, short-chain fatty acids. Created with BioRender.com [rerif]

impact of the menstrual cycle on glucose metabolism seems to be multifactorial and systemic, since effects in different tissues have been observed (as outlined previously). Therefore, the association between sex hormones and glucose metabolism may be better reflected by more physiological conditions during OGTT involving the gastrointestinal tract.

### Impact of blood sampling method on glucose values

Another factor that can influence the measured glucose values is the blood collection method. Glucose values obtained by venous blood sampling were significantly lower than those obtained by capillary blood sampling, especially during the OGTT [74]. Most studies, except those by Jarrett and Graver and Pepler et al., performed venous blood sampling. Consequently, the direct comparison of glucose values between studies was limited. However, the differences between the cycle phases within these studies should not have been affected by this.

In addition, the duration of the OGTT and the time points at which the blood samples were collected could have affected the results. This might explain the lack of statistically significant results reported by Williams et al. Here, blood samples were collected only in a fasting state and after 30 minutes [42]. Thus, there is a possibility that phase-specific differences in glucose levels may have

been overlooked. This approach was motivated by reports showing that glucose and insulin levels were the highest during oral glucose loading at this point [42]. However, Brennan et al. showed that fluctuations could still occur after the first 30 minutes of the OGTT [41]. Similarly, Busby et al. only measured fasting and 120-minute glucose values [40]. Blood glucose levels 120 minutes after glucose administration were similar to those in the fasting state. Therefore, mild fluctuations might have remained undiscovered. Lin et al. addressed the issue of limited blood sampling time points by analyzing glucose variance in the course of the menstrual cycle using continuous glucose measurement. While not performing an OGTT, their results support the findings of Jarrett and Graver, Pepler et al., and Brennan et al., as they found that glucose values were the lowest during late FP, increased during ovulation, and peaked in the LP phase [75].

### Impact of measurement time points during the menstrual cycle on the assessment of glucose metabolism

There is high variability among the studies in the time points (i. e., cycle days) chosen across the menstrual cycle to represent the different cycle phases, which leads to inconsistent assignment of measurements to the cycle phases. In the study by Walsh and

O'Sullivan, the time points examined were initially divided into menstrual cycle quarters, which could be assigned to the MP, FP, and LP by specifying the days on which the blood samples were collected. However, because Walsh and O'Sullivan did not determine the timing of their subjects' ovulation, days 17 and 18 (the third quarter of the menstrual cycle) could represent late FP, ovulation, or early LP, respectively [36]. This depends on the individual variation in menstrual cycle length and the time of ovulation, with both showing high variability in the general population [29]. A similar approach was adopted by Jarrett and Graver with weekly examinations. Similarly, the key ovulation time point, which defines the transition from FP to LP, was determined only in a small subgroup of two participants [34]. To be able to distinguish the values of the FP from those of the LP more clearly, it would have been useful to clearly determine the time point of ovulation. Another suboptimal method for classifying the menstrual cycle phases was performed by Pepler et al. [37] using self-administered questionnaires to classify the menstrual cycle phase, which is prone to error (misclassification bias [76]). In contrast, Brennan et al. measured the hormone concentrations [41]. In conclusion, future studies should accurately classify menstrual cycle phases and determine ovulation by recording LH, estrogen, and progesterone concentrations, or by using another accurate method [77].

### Considering inter-cycle variability to enhance reproducibility

Inter-cycle variability within a single participant raises the issue of reproducibility. Duplicate tests conducted in the FP by Brennan et al. did not show significant differences [41]. The glucose values collected in the FP were reproducible over two cycles, indicating that intra-individual variations were not the driving factor of variance during the menstrual cycles (► Fig. 2). Similar results were reported by Jarrett and Graver, in which a small subcohort of three women underwent repeated examinations in subsequent cycles. The patterns of the glucose values appeared similar, although no statistical tests were performed [34]. Cudworth et al. also did not detect significant differences in blood sugar-time areas between two cycles in a sub-cohort of seven women [35]. Pepler et al. investigated the reproducibility of glucose values in the LP in addition to the MP/FP. For this purpose, a double examination of 192 female participants was performed. The results showed that glucose values in the MP/FP were reproducible by 60%, whereas those in the LP were only by 25%. This indicates that a greater variation in glucose levels may be present during the second half of the menstrual cycle [37]. Ideally, studies should be performed over more than two menstrual cycles in the same participants to provide greater confidence in the reproducibility of glucose values and capture intra- and inter-individual differences.

### Interactions between the gut microbiota, glucose homeostasis, and sex hormones

The gut microbiota significantly impacts host metabolism and the etiology of metabolic diseases. Type 2 and gestational diabetes have been linked to changes in the gut microbiota (dysbiosis), indicating a key role of the microbiota in host glucose metabolism [25]. In a recent scoping review, 40 bacterial taxa were associated with glucose-related parameters and 17 with insulin-related out-

comes. Five of these bacterial taxa (*Akkermansia muciniphila*, *Bifidobacterium longum*, *Clostridium leptum* group, *Faecalibacterium prausnitzii*, *Faecalibacterium*) were the taxa most frequently and inversely associated with glucose levels [78]. The various pathways along the microbiota-gut-brain axis and microbiota-gut-liver axis by which the gut microbiota affects glucose homeostasis have been reviewed in detail elsewhere [79–81]. For instance, microbial metabolites such as short-chain fatty acids butyrate, acetate, and propionate can modulate glucose metabolism by reducing the glycaemic response by affecting glucose uptake. In addition, short-chain fatty acids, as well as nutrient intake, stimulate the secretion of the gut hormones GLP-1, GLP-2, and PYY from intestinal endocrine cells, affecting glucose and insulin metabolism, gastrointestinal motility, appetite, and microbiome composition [25, 78].

Another mechanism linking the gut microbiota, glucose metabolism, and menstrual cycle might be the gut transit time, which is regulated by gut hormones as well as the enteric nervous system [80]. While the upper intestinal transit time (gastric emptying and small intestinal motility) affects the glycaemic responses to a meal, the lower intestinal transit time (colonic transit time) has a more pronounced effect on the gut microbiota. Colonic transit time has been associated with microbiome composition and the relative abundance of certain species, as well as with postprandial glucose metabolism [82], recently also in a study with more than 800 participants [83]. Moreover, the intestinal transit time has been shown to vary between cycle phases in some early studies [84, 85], whereas others have detected no differences [86]. The underlying mechanisms remain to be elucidated, but progesterone levels have been hypothesized to be relevant, potentially influencing gut motility via intestinal muscle contraction and alterations in gastrointestinal hormones (e. g., motilin). The effect of progesterone on gut motility is dose-dependent [87, 88]. Low progesterone doses, in comparison to pregnancy, increase the gastric emptying rate with higher postprandial glucose, insulin, and GLP-1 levels and can also disturb the microbiota diversity through frequent bowel movement [41, 82]. On the other hand, higher progesterone levels, as present in the second and third trimester of pregnancy, can decrease intestinal motility and prolong gastrointestinal transit time [88–90] but can impair glucose tolerance by affecting glucose transporters in skeletal muscles and enhancing hepatic gluconeogenesis, especially in susceptible patients with limited insulin secretion or suffering from sub-clinical insulin resistance [91, 92]. In addition, changes in food intake (e. g., fibers) and physical activity that can occur depending on the cycle (as described previously) can also affect the transit time [82, 93]. Hence, a variation in transit time in relation to sex hormones might affect the gut microbiome composition as well as glucose metabolism and should be assessed, along with the underlying mechanisms, in future studies.

Another pathway affecting glucose homeostasis and sex steroid hormone synthesis is the metabolism of bile acids, which is largely influenced by microbiota. By metabolizing primary bile acids to secondary bile acids and activating bile acid receptors in the intestine, the gut microbiota can affect the secretion of GLP-1, insulin sensitivity, and glucose tolerance by activating the transcription factor FXR or G protein-coupled bile acid receptor 1 (TGR5) [79, 81]. Sex hormones are metabolized via an enterohepatic cycle that depends on biologically active gut microbiota. They pass through a



cycle that includes biliary excretion (approximately 60% [94]), bacterial deconjugation, and intestinal reabsorption. Deconjugation is necessary for the absorption of circulating estrogens, in which the gut microbiota plays an important role [95]. In addition to bile acids, microbial enzyme activity, and microbially activated phytoestrogens can also affect sex hormone metabolism [21].

Furthermore, changes in the gut microbiota are associated with diseases related to the menstrual cycle, such as polycystic ovarian syndrome (PCOS) and irregular (anovulatory) menstrual cycle [96, 97]. However, the influence of pathophysiological impairments on the menstrual cycle and microbiome should be the subject of a separate review. Here, the interaction between sex hormones and gut microbiota is reviewed, considering studies that have examined the influence of hormonal contraceptives on fecal microbiota. Studies in rodents have shown an influence of sex hormones on the gut microbiota [95], which might impact the state of health [95, 98], while results of human observational studies indicate that the  $\beta$ -diversity of the gut microbiota is not affected by hormonal contraceptives [99, 100]. With regard to  $\alpha$ -diversity, the results of a study by Krog et al. indicate that there are no differences [100] while Mihajlovic et al. found a slightly higher  $\alpha$ -diversity in the control group compared to the group using hormonal contraceptives. Three genera—*Eubacterium*, *Haemophilus*, and unclassified *Firmicutes*—were enriched in the control group, whereas two genera, *Akkermansia* and *Barnesiella*, were enriched in the contraceptive group. These differences may be due to the decreased estrogen and progesterone concentrations caused by the use of hormonal contraceptives [99]. Furthermore, they hypothesized that lower concentrations are also the cause of *Akkermansia* accumulation, as animal studies indicate that mice treated with conjugated estrogens [101] have lower concentrations of *Akkermansia*. Hence, Mihajlovic et al. assumed a negative correlation between *Akkermansia* and estrogens.

### Associations between menstrual cycle phases and the gut microbiota

Data on the possible associations between gut microbiota and the physiological menstrual cycle are limited. In a study by Mihajlovic et al., stool samples were collected continuously over the course of a 28-day menstrual cycle. While there was no significant difference in  $\alpha$  or  $\beta$ -diversity between LP and FP, taxonomic analysis detected *Akkermansia* and *Lactococcus* in higher abundances (4-fold and 2-fold) in the LP compared to the FP. Based on the suspected negative correlation between *Akkermansia* and estrogens, the authors expected that *Akkermansia* would be reduced during the LP (high estrogen concentrations) compared to the FP, which was not the case. Thus, Mihajlovic et al. concluded that the estrogen concentration exerts a complex function in *Akkermansia* growth. In this regard, there might be a sensitive response by *Akkermansia* to circulating estrogen and progesterone levels, whereas the increase in *Lactococcus* in the LP is assumed to be influenced by rising estrogen concentrations [99]. However, these results need to be interpreted with caution, as they are derived from one study with a small cohort of 16 women, nine of whom were in the group with a physiological menstrual cycle. *Akkermansia* has been negatively associated with type 2 diabetes and obesity in humans and has shown beneficial effects on glucose metabolism in animal studies [25, 81].

Strains of *Akkermansia muciniphila* are commonly present in the human gut and positively impact host health by strengthening intestinal barrier integrity and promoting anti-inflammatory actions. Bacterial species of the *Lactococcus* genus are lactic acid producers frequently used in the production of fermented foods and probiotics. As the methods applied in the study by Mihajlovic et al. did not allow taxa differentiation below the genus level, it is difficult to draw concise conclusions about the health implications of the enrichment of *Akkermansia* and *Lactococcus* detected in the LP, as the effects are often species- or strain-specific.

Krog et al. investigated changes in the microbial composition of different body sites (saliva, vagina, feces, and rectum) during menstruation, FP, and LP in a cohort of 160 participants (54 of these had a physiological cycle). While vaginal microbial diversity differed significantly between cycle phases, no differences were detected in other body sites, including feces. In general, shifts in microbiome composition were subtle in fecal samples and the highest in vaginal samples. Estradiol and progesterone levels were not correlated with fecal microbiome composition [100].

One observational study focusing on the temporal variability in gut microbiome profiles by continuous stool sample analysis over six weeks in 20 women found high day-to-day inter-individual variations. However, these variations were not significantly influenced by the menstrual cycle parameters [102]. This highlights the difficulty in interpreting studies examining the relationship between the gut microbiota and sex hormones, as estrogen and progesterone levels fluctuate throughout the menstrual cycle with similar times for rising and falling concentrations. Hence, the effects of individual sex hormones may only be clearly differentiable [99] if both sex hormones and the composition of the gut microbiota are examined using continuous sample collection during the menstrual cycle.

### Conclusion

To date, data on the changes in glucose metabolism and gut microbiota during the course of the menstrual cycle are limited. The results of previous studies on the respective topic suggest that there may be phase-specific variations induced by fluctuations in sex hormone concentrations. Therefore, when assessing glucose tolerance in women, the phase of the menstrual cycle at which the OGTT is performed may be relevant, as the greatest glucose tolerance appears to occur during the onset of the menstrual cycle (FP).

Several factors, such as age, BMI, diet, physical activity, health status, and medication, can influence the mutual relationship of glucose metabolism and gut microbiota with the menstrual cycle (► Fig. 3). In addition, the methodological issues of the studies have been outlined, which might explain the inhomogeneity of the study results. Therefore, future studies should carefully consider these confounding factors. For example, standardized implementation of the OGTT (glucose load, carbohydrate intake, and physical activity) is relevant for obtaining reliable and comparable results. Moreover, continuous glucose measurements may be preferable to examine the differences in glucose levels more precisely and over the course of the entire menstrual cycle. To determine systematic cycle-dependent fluctuations, the reproducibility of glucose values in the respective cycle phases must be recorded by collecting data from multiple cycles. In addition, recording hor-

more concentrations may be essential for the precise classification of the menstrual cycle phases (FP and LP) and ovulation time. Recording the habitual diet and composition of the gut microbiota is also relevant for the transferability and comparability of the results.

The extent to which variations in glucose metabolism during the different menstrual cycle phases, shown in some studies, are associated with changes in the gut microbiota is not fully understood. Accordingly, there is a need for future research to investigate the interplay between glucose metabolism and the gut microbiota in relation to sex hormones in a healthy group of participants with a regular menstrual cycle.

Phase-specific variations in glucose tolerance may have implications for diabetes management, as the required doses of diabetes medication may also be dependent on the cycle, possibly requiring adjustment of the medication (e. g., insulin dose). A personalized diet adapted to glucose tolerance in correspondence with the menstrual cycle may prospectively improve female health or prevent diabetes in women at high risk.

## Authors' contributions

SK and AS conducted the research and prepared the first draft of the manuscript, which was subsequently finalized in close collaboration with MCS and TP. All authors provided substantial content contributions and edited the manuscript. MCS provided the initial ideas for this manuscript. SK and AS created and edited the table. AS and MCS created and edited the figures. All the authors have read and approved the final manuscript.

## Funding Information

German Federal Ministry of Education and Research — 01EA1707 ImmunoSensation —

German Diabetes Association —

AS and MCS are supported by funding from the German Federal Ministry of Education and Research (*Bundesministerium für Bildung und Forschung*, BMBF), grant number: 01EA1707. MCS received funding from ImmunoSensation and the German Diabetes Association.

## Acknowledgement

Some of the figures were created using Bio-Render.com.

## Conflict of interest

The authors declare that they have no conflict of interest.

## References

- [1] World Health Organization. Non communicable diseases. 2022. <https://www.who.int/news-room/fact-sheets/detail/noncommunicable-diseases>
- [2] Sun H, Saeedi P, Karuranga S et al. IDF Diabetes Atlas: Global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045. *Diabetes Res Clin Pract* 2022; 183: 109119
- [3] Boyns DR, Crossley JN, Abrams ME et al. Oral glucose tolerance and related factors in a normal population sample. I. Blood sugar, plasma insulin, glyceride, and cholesterol measurements and the effects of age and sex. *Br Med J* 1969; 1: 595–598
- [4] Macdonald I, Crossley JN. Glucose tolerance during the menstrual cycle. *Diabetes* 1970; 19: 450–452
- [5] Bundesärztekammer BÄK. Kassenärztliche Bundesvereinigung (KBV), Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF). Nationale VersorgungsLeitlinie Typ-2-Diabetes – Langfassung, Version 3: 0 2023
- [6] Blaak EE. Sex differences in the control of glucose homeostasis. *Curr Opin Clin Nutr Metab Care* 2008; 11: 500–504
- [7] Flanagan DE, Holt RIG, Owens PC et al. Gender differences in the insulin-like growth factor axis response to a glucose load. *Acta Physiologica* 2006; 187: 371–378
- [8] Basu R, Dalla Man C, Campioni M et al. Effects of age and sex on postprandial glucose metabolism: Differences in glucose turnover, insulin secretion, insulin action, and hepatic insulin extraction. *Diabetes* 2006; 55: 2001–2014
- [9] Borissova A-M, Tankova T, Kirilov G et al. Gender-dependent effect of ageing on peripheral insulin action. *Int J Clin Pract* 2005; 59: 422–426
- [10] Frias JP, Macaraeg GB, Ofrecio J et al. Decreased susceptibility to fatty acid-induced peripheral tissue insulin resistance in women. *Diabetes* 2001; 50: 1344–1350
- [11] Perseghin G, Scifo P, Pagliato E et al. Gender factors affect fatty acids-induced insulin resistance in nonobese humans: effects of oral steroidal contraception. *J Clin Endocrinol Metab* 2001; 86: 3188–3196
- [12] Gaete X, Vivanco M, Eyzaguirre FC et al. Menstrual cycle irregularities and their relationship with HbA1c and insulin dose in adolescents with type 1 diabetes mellitus. *Fertil Steril* 2010; 94: 1822–1826
- [13] Brown SA, Jiang B, McElwee-Malloy M et al. Fluctuations of hyperglycemia and insulin sensitivity are linked to menstrual cycle phases in women with T1D. *J Diabetes Sci Technol* 2015; 9: 1192–1199
- [14] Cramer HI. The influence of menstruation on carbohydrate tolerance in diabetes mellitus. *Can Med Assoc J* 1942; 47: 51–55
- [15] Walsh CH, Malins JM. Menstruation and control of diabetes. *Br Med J* 1977; 2: 177–179
- [16] Milionis C, Ilias I, Venaki E et al. The effect of menstrual hormonal fluctuations on the glycaemic control in women with type 1 diabetes mellitus. *Practical Diabetes* 2023; 40: 35–39
- [17] Ezenwaka EC, Akanji AO, Adejuwon CA et al. Insulin responses following glucose administration in menstruating women. *Int J Gynaecol Obstet* 1993; 42: 155–159
- [18] van Genugten RE, Utzschneider KM, Tong J et al. Effects of sex and hormone replacement therapy use on the prevalence of isolated impaired fasting glucose and isolated impaired glucose tolerance in subjects with a family history of type 2 diabetes. *Diabetes* 2006; 55: 3529–3535
- [19] Kim YS, Unno T, Kim BY et al. Sex differences in gut microbiota. *World J Mens Health* 2020; 38: 48–60
- [20] Adlercreutz H, Martin F. Oestrogen in human pregnancy faeces. *Acta Endocrinologica* 1976; 83: 410–419
- [21] Santos-Marcos JA, Mora-Ortiz M, Tena-Sempere M et al. Interaction between gut microbiota and sex hormones and their relation to sexual dimorphism in metabolic diseases. *Biol Sex Differ* 2023; 14: 4
- [22] Wu H, Ballantyne CM. Metabolic inflammation and insulin resistance in obesity. *Circ Res* 2020; 126: 1549–1564
- [23] Kinoshita M, Suzuki Y, Saito Y. Butyrate reduces colonic paracellular permeability by enhancing PPARgamma activation. *Biochem Biophys Res Commun* 2002; 293: 827–831

- [24] Isayama K, Rini DM, Yamamoto Y et al. Propionate regulates tight junction barrier by increasing endothelial-cell selective adhesion molecule in human intestinal Caco-2 cells. *Exp Cell Res* 2023; 425: 113528
- [25] Zhou Z, Sun B, Yu D et al. Gut microbiota: An important player in type 2 diabetes mellitus. *Front Cell Infect Microbiol* 2022; 12: 834485
- [26] Arora T, Bäckhed F. The gut microbiota and metabolic disease: Current understanding and future perspectives. *J Intern Med* 2016; 280: 339–349
- [27] van Deuren T, Blaak EE, Canfora EE. Butyrate to combat obesity and obesity-associated metabolic disorders: Current status and future implications for therapeutic use. *Obes Rev* 2022; 23: e13498
- [28] Fillenberg S. Der menstruelle Zyklus. In: Lasch L, Fillenberg S, eds. *Basiswissen Gynäkologie und Geburtshilfe*. 1st ed. Berlin: Springer; 2017: 134–136
- [29] Bull JR, Rowland SP, Scherwitzl EB et al. Real-world menstrual cycle characteristics of more than 600,000 menstrual cycles. *NPJ Digit Med* 2019; 2: 83
- [30] Tramunt B, Smati S, Grandgeorge N et al. Sex differences in metabolic regulation and diabetes susceptibility. *Diabetologia* 2020; 63: 453–461
- [31] Anagnostis P, Christou K, Artzouchaltzi A-M et al. Early menopause and premature ovarian insufficiency are associated with increased risk of type 2 diabetes: A systematic review and meta-analysis. *Eur J Endocrinol* 2019; 180: 41–50
- [32] Kanaya AM, Herrington D, Vittinghoff E et al. Glycemic effects of postmenopausal hormone therapy: The Heart and Estrogen/progestin Replacement Study. A randomized, double-blind, placebo-controlled trial. *Ann Intern Med* 2003; 138: 1–9
- [33] Margolis KL, Bonds DE, Rodabough RJ et al. Effect of oestrogen plus progestin on the incidence of diabetes in postmenopausal women: Results from the Women's Health Initiative Hormone Trial. *0012-186X* 2004; 47: 1175–1187
- [34] Jarrett RJ, Graver HJ. Changes in oral glucose tolerance during the menstrual cycle. *Br Med J* 1968; 2: 528–529
- [35] Cudworth AG, Veevers A. Carbohydrate metabolism in the menstrual cycle. *Br J Obstet Gynaecol* 1975; 82: 162–169
- [36] Walsh CH, O'Sullivan DJ. Studies of glucose tolerance, insulin and growth hormone secretion during the menstrual cycle in healthy women. *Ir J Med Sci* 1975; 144: 18–24
- [37] Peppler U, Thefeld W, Wincenty U. Oraler Glukosetoleranztest bei Frauen in Abhängigkeit vom Menstruationszyklus. *Klin Wochenschr* 1978; 56: 659–669
- [38] Bonora E, Zavaroni I, Alpi O et al. Influence of the menstrual cycle on glucose tolerance and insulin secretion. *AJOG* 1987; 157: 140–141
- [39] Toth EL, Suthijumroon A, Crockford PM et al. Insulin action does not change during the menstrual cycle in normal women. *J Clin Endocrinol Metab* 1987; 64: 74–80
- [40] Busby MJ, Bellantoni MF, Tobin JD et al. Glucose tolerance in women: The effects of age, body composition, and sex hormones. *J Am Geriatr Soc* 1992; 40: 497–502
- [41] Brennan IM, Feltrin KL, Nair NS et al. Effects of the phases of the menstrual cycle on gastric emptying, glycemia, plasma GLP-1 and insulin, and energy intake in healthy lean women. *Am J Physiol Gastrointest Liver Physiol* 2009; 297: 602–610
- [42] Williams JS, Stimpson TV, Tremblay JC et al. The influence of acute hyperglycaemia on brachial artery flow-mediated dilatation in the early and late follicular phases of the menstrual cycle. *Exp Physiol* 2019; 104: 957–966
- [43] Varlamov O, Bethea CL, Roberts CT. Sex-specific differences in lipid and glucose metabolism. *Front Endocrinol (Lausanne)* 2014; 5: 241
- [44] Godsland IF. Oestrogens and insulin secretion. *Diabetologia* 2005; 48: 2213–2220
- [45] Kasarinaite A, Sinton M, Saunders PTK et al. The influence of sex hormones in liver function and disease. *Cells* 2023; 12:
- [46] Spellacy WN, Carlson KL, Schade SL. Menstrual cycle carbohydrate metabolism: Studies on plasma insulin and blood glucose levels during an intravenous glucose tolerance test. *AJOG* 1967; 99: 382–386
- [47] Kumagai S, Holmäng A, Björntorp P. The effects of oestrogen and progesterone on insulin sensitivity in female rats. *Acta Physiol Scand* 1993; 149: 91–97
- [48] Yki-Järvinen H. Insulin sensitivity during the menstrual cycle. *J Clin Endocrinol Metab* 1984; 59: 350–353
- [49] Valdes CT, Elkind-Hirsch KE. Intravenous glucose tolerance test-derived insulin sensitivity changes during the menstrual cycle. *J Clin Endocrinol Metab* 1991; 72: 642–646
- [50] MacGregor KA, Gallagher IJ, Moran CN. Relationship between insulin sensitivity and menstrual cycle is modified by BMI, fitness, and physical activity in NHANES. *J Clin Endocrinol Metab* 2021; 106: 2979–2990
- [51] Pulido JME, Salazar MA. Changes in insulin sensitivity, secretion and glucose effectiveness during menstrual cycle. *Arch Med Res* 1999; 30: 19–22
- [52] Yeung EH, Zhang C, Mumford SL et al. Longitudinal study of insulin resistance and sex hormones over the menstrual cycle: The BioCycle Study. *J Clin Endocrinol Metab* 2010; 95: 5435–5442
- [53] Zarei S, Mosalanejad L, Ghobadifar MA. Blood glucose levels, insulin concentrations, and insulin resistance in healthy women and women with premenstrual syndrome: A comparative study. *Clin Exp Reprod Med* 2013; 40: 76–82
- [54] Hummel J, Benkendorff C, Fritsche L et al. Brain insulin action on peripheral insulin sensitivity in women depends on menstrual cycle phase. *Nat Metab* 2023; 5: 1475–1482
- [55] Bingley CA, Gitau R, Lovegrove JA. Impact of menstrual cycle phase on insulin sensitivity measures and fasting lipids. *Horm Metab Res* 2008; 40: 901–906
- [56] Mayer EJ, Newman B, Austin MA et al. Genetic and environmental influences on insulin levels and the insulin resistance syndrome: an analysis of women twins. *Am J Epidemiol* 1996; 143: 323–332
- [57] Clarke SL, Reaven GM, Leonard D et al. Cardiorespiratory fitness, body mass index, and markers of insulin resistance in apparently healthy women and men. *Am J Med* 2020; 133: 825–830
- [58] Batista MC, Cartledge TP, Zellmer AW et al. Effects of aging on menstrual cycle hormones and endometrial maturation. *Fertil Steril* 1995; 64: 492–499
- [59] Lasqueti MG, Rodriguez D, Fehring RJ. The influence of BMI levels on phases of the menstrual cycle and presumed ovulation. *Linacre Q* 2012; 79: 451–459
- [60] Knuth UA, Hull MGR, Jacobs HS. Amenorrhoea and loss of weight. *Br J Obstet Gynaecol* 1977; 84: 801–807
- [61] Webb P. 24-hour energy expenditure and the menstrual cycle. *AJCN* 1986; 44: 614–619
- [62] Solomon SJ, Kurzer MS, Calloway DH. Menstrual cycle and basal metabolic rate in women. *AJCN* 1982; 36: 611–616
- [63] Anyanwagu U, Idris I, Donnelly R. Drug-induced diabetes mellitus: Evidence for statins and other drugs affecting glucose metabolism. *Clin Pharmacol Ther* 2016; 99: 390–400
- [64] Cagnacci A, Biasioli A. The Effect of Hormonal Contraceptives on Metabolism. In: Meriggola MC, Gemzell-Danielsson K, eds. *Female and male contraception. Trends in andrology and sexual medicine*. 1st ed. Cham: Springer International Publishing; Imprint Springer; 2021: 299–317

- [65] Godsland IF, Crook D, Simpson R et al. The effects of different formulations of oral contraceptive agents on lipid and carbohydrate metabolism. *N Engl J Med* 1990; 323: 1375–1381
- [66] van der Vange N, Kloosterboer HJ, Haspels AA. Effect of seven low-dose combined oral contraceptive preparations on carbohydrate metabolism. *AJOG* 1987; 156: 918–922
- [67] Catalano PM, Tyzbir ED, Roman NM et al. Longitudinal changes in insulin release and insulin resistance in nonobese pregnant women. *AJOG* 1991; 165: 1667–1672
- [68] Adam S, McIntyre HD, Tsoi KY et al. Pregnancy as an opportunity to prevent type 2 diabetes mellitus: FIGO Best Practice Advice. *Int J Gynaecol Obstet* 2023; 160: 56–67
- [69] World Health Organization. Definition, diagnosis and classification of diabetes mellitus and its complications: Report of a WHO consultation. Part 1: diagnosis and classification of diabetes mellitus 1999, <https://apps.who.int/iris/handle/10665/66040>
- [70] Horowitz M, Edelbroek MAL, Wishart JM et al. Relationship between oral glucose tolerance and gastric emptying in normal healthy subjects. *Diabetologia* 1993; 36: 857–862
- [71] Titchenal CA, Hatfield K, Dunn M et al. Does prior exercise affect oral glucose tolerance test results? *JISSN* 2008; 5: Suppl 1
- [72] Prystupa K, Renklint R, Chninou Y et al. Comprehensive validation of fasting-based and oral glucose tolerance test-based indices of insulin secretion against gold standard measures. *BMJ Open Diabetes Res Care* 2022; 10: e002909
- [73] Bergman RN, Finegood DT, Ader M. Assessment of insulin sensitivity in vivo. *Endocr Rev* 1985; 6: 45–86
- [74] Ignell C, Berntorp K. Evaluation of the relationship between capillary and venous plasma glucose concentrations obtained by the HemoCue Glucose 201 + system during an oral glucose tolerance test. *Scand J Clin Lab Invest* 2011; 71: 670–675
- [75] Lin G, Siddiqui R, Lin Z et al. Blood glucose variance measured by continuous glucose monitors across the menstrual cycle. *NPJ Digit Med* 2023; 6: 140
- [76] Porta M, Greenland S, Hernán MS et al. A dictionary of Epidemiology. 6th ed. Oxford University Press: Oxford, 2014
- [77] Su H-W, Yi Y-C, Wei T-Y et al. Detection of ovulation, a review of currently available methods. *Bioeng Transl Med* 2017; 2: 238–246
- [78] Palmnäs-Bédard MSA, Costabile G, Vetrani C et al. The human gut microbiota and glucose metabolism: A scoping review of key bacteria and the potential role of SCFAs. *AJCN* 2022; 116: 862–874
- [79] Wachsmuth HR, Weninger SN, Duca FA. Role of the gut-brain axis in energy and glucose metabolism. *Exp Mol Med* 2022; 54: 377–392
- [80] Simon M-C, Sina C, Ferrario PG et al. Gut microbiome analysis for personalized nutrition: The state of science. *Mol Nutr Food Res* 2023; 67: e2200476
- [81] Zhou Y-D, Liang F-X, Tian H-R et al. Mechanisms of gut microbiota-immune-host interaction on glucose regulation in type 2 diabetes. *1664-302X* 2023; 14: 1121695
- [82] Müller M, Canfora EE, Blaak EE. Gastrointestinal transit time, glucose homeostasis and metabolic health: Modulation by dietary fibers. *Nutrients* 2018; 10: 275
- [83] Asnicar F, Leeming ER, Dimidi E et al. Blue poo: Impact of gut transit time on the gut microbiome using a novel marker. *Gut* 2021; 70: 1665–1674
- [84] Jung H-K, Kim D-Y, Moon I-H. Effects of gender and menstrual cycle on colonic transit time in healthy subjects. *Korean J Intern Med* 2003; 18: 181–186
- [85] Córdova-Fraga T, Huerta-Franco R, Gutiérrez-Juárez G et al. The colon transit time in different phases of the menstrual cycle: Assessed with biomagnetic technique. *Neurol Clin Neurophysiol* 2004; 2004: 31
- [86] Kamm MA, Farthing MJ, Lennard-Jones JE. Bowel function and transit rate during the menstrual cycle. *0017-5749* 1989; 30: 605–608
- [87] Liu C-Y, Chen L-B, Liu P-Y et al. Effects of progesterone on gastric emptying and intestinal transit in male rats. *World J Gastroenterol* 2002; 8: 338
- [88] Matos JF, Americo MF, Sinzato YK et al. Role of sex hormones in gastrointestinal motility in pregnant and non-pregnant rats. *World J Gastroenterol* 2016; 22: 5761
- [89] Lawson M, Kern F, Everson GT. Gastrointestinal transit time in human pregnancy: Prolongation in the second and third trimesters followed by postpartum normalization. *Gastroenterology* 1985; 89: 996–999
- [90] Chiloiro M, Darconza G, Piccioli E et al. Gastric emptying and orocecal transit time in pregnancy. *J Gastroenterol* 2001; 36: 538–543
- [91] Wada T, Hori S, Sugiyama M et al. Progesterone inhibits glucose uptake by affecting diverse steps of insulin signaling in 3T3-L1 adipocytes. *Am J Physiol Endocrinol Metab* 2010; 298: E881–E888
- [92] Lee SR, Choi W-Y, Heo JH et al. Progesterone increases blood glucose via hepatic progesterone receptor membrane component 1 under limited or impaired action of insulin. *Sci Rep* 2020; 10: 16316
- [93] Jensen MM, Pedersen HE, Clemmensen KKB et al. Associations between physical activity and gastrointestinal transit times in people with normal weight, overweight, and obesity. *J Nutr* 2024; 154: 41–48
- [94] Sandberg AA, Slaunwhite WR Jr. Studies on phenolic steroids in human subjects. VII. Metabolic fate of estriol and its glucuronide. *J Clin Invest* 1965; 44: 694–702
- [95] Benedek G, Zhang J, Nguyen H et al. Estrogen protection against EAE modulates the microbiota and mucosal-associated regulatory cells. *J Neuroimmunol* 2017; 310: 51–59
- [96] Sasaki H, Kawamura K, Kawamura T et al. Distinctive subpopulations of the intestinal microbiota are present in women with unexplained chronic anovulation. *Reprod Biomed Online* 2019; 38: 570–578
- [97] Liang Z, Di N, Li L et al. Gut microbiota alterations reveal potential gut-brain axis changes in polycystic ovary syndrome. *J Endocrinol Invest* 2021; 44: 1727–1737
- [98] Acharya KD, Gao X, Bless EP et al. Estradiol and high fat diet associate with changes in gut microbiota in female ob/ob mice. *Sci Rep* 2019; 9: 20192
- [99] Mihajlovic J, Leutner M, Hausmann B et al. Combined hormonal contraceptives are associated with minor changes in composition and diversity in gut microbiota of healthy women. *Environ Microbiol* 2021; 23: 3037–3047
- [100] Krog MC, Hugerth LW, Fransson E et al. The healthy female microbiome across body sites: Effect of hormonal contraceptives and the menstrual cycle. *Hum Reprod* 2022; 37: 1525–1543
- [101] Chen KLA, Liu X, Zhao YC et al. Long-term administration of conjugated estrogen and bazedoxifene decreased murine fecal  $\beta$ -glucuronidase activity without impacting overall microbiome community. *Sci Rep* 2018; 8: 8166
- [102] Vandeputte D, Commer L, Tito RY et al. Temporal variability in quantitative human gut microbiome profiles and implications for clinical research. *Nat Commun* 2021; 12: 6740
- [103] Welt CK. Normal menstrual cycle. 17 April 2023. [https://www.uptodate.com/contents/normal-menstrual-cycle?search=physiology-of-the-normal-menstrual&source=search\\_result&selectedTitle=1~150&usage\\_type=default&display\\_rank=1#H176499083](https://www.uptodate.com/contents/normal-menstrual-cycle?search=physiology-of-the-normal-menstrual&source=search_result&selectedTitle=1~150&usage_type=default&display_rank=1#H176499083) [cited 2023 Oct 23]